Ease of Use
Viatris Inc is a drug manufacturers—specialty & generic business based in the US. Viatris shares (MYL.US) are listed on the NASDAQ and all prices are listed in US Dollars. Its last market close was $15.6 – a decrease of 0.7% over the previous week. Viatris employs 35,000 staff and has a trailing 12-month revenue of around $11.5 billion.
Since the stock market crash in March caused by coronavirus, Viatris's share price has had significant negative movement.
Its last market close was $15.6, which is 26.24% down on its pre-crash value of $21.15 and 22.35% up on the lowest point reached during the March crash when the shares fell as low as $12.75.
If you had bought $1,000 worth of Viatris shares at the start of February 2020, those shares would have been worth $727.98 at the bottom of the March crash, and if you held on to them, then as of the last market close they'd be worth $721.50.
|Latest market close||$15.6|
|52-week range||$0.077 - $23.11|
|50-day moving average||$15.4929|
|200-day moving average||$15.9885|
|Wall St. target price||$21.75|
|Dividend yield||N/A (0%)|
|Earnings per share (TTM)||$0.516|
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
|1 week (2020-11-17)||19,646.84%|
|1 month (2020-10-23)||-0.57%|
|3 months (2020-08-25)||-2.68%|
|6 months (2020-05-22)||-0.26%|
|1 year (2019-11-22)||-10.03%|
|2 years (2018-11-23)||-53.42%|
|3 years (2017-11-24)||-58.26%|
|5 years (2015-11-24)||-69.04%|
Valuing Viatris stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of Viatris's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.
Viatris's current share price divided by its per-share earnings (EPS) over a 12-month period gives a "trailing price/earnings ratio" of roughly 33x. In other words, Viatris shares trade at around 33x recent earnings.
That's relatively high compared to, say, the trailing 12-month P/E ratio for the NASDAQ 100 at the end of 2019 (27.29). The high P/E ratio could mean that investors are optimistic about the outlook for the shares or simply that they're over-valued.
Viatris's "price/earnings-to-growth ratio" can be calculated by dividing its P/E ratio by its growth – to give 1.59. A low ratio can be interpreted as meaning the shares offer better value, while a higher ratio can be interpreted as meaning the shares offer worse value.
The PEG ratio provides a broader view than just the P/E ratio, as it gives more insight into Viatris's future profitability. By accounting for growth, it could also help you if you're comparing the share prices of multiple high-growth companies.
Viatris's EBITDA (earnings before interest, taxes, depreciation and amortisation) is USD$3.5 billion.
The EBITDA is a measure of a Viatris's overall financial performance and is widely used to measure a its profitability.
|Revenue TTM||USD$11.5 billion|
|Operating margin TTM||15.72%|
|Gross profit TTM||USD$4.6 billion|
|Return on assets TTM||3.63%|
|Return on equity TTM||0%|
|Market capitalisation||USD$8.6 billion|
TTM: trailing 12 months
There are currently 47.1 million Viatris shares held short by investors – that's known as Viatris's "short interest". This figure is 1.4% up from 46.5 million last month.
There are a few different ways that this level of interest in shorting Viatris shares can be evaluated.
Viatris's "short interest ratio" (SIR) is the quantity of Viatris shares currently shorted divided by the average quantity of Viatris shares traded daily (recently around 4.2 million). Viatris's SIR currently stands at 11.15. In other words for every 100,000 Viatris shares traded daily on the market, roughly 11150 shares are currently held short.
However Viatris's short interest can also be evaluated against the total number of Viatris shares, or, against the total number of tradable Viatris shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Viatris's short interest could be expressed as 0.09% of the outstanding shares (for every 100,000 Viatris shares in existence, roughly 90 shares are currently held short) or 0.1105% of the tradable shares (for every 100,000 tradable Viatris shares, roughly 111 shares are currently held short).
A SIR above 10% would generally be considered pretty high, pointing to a potentially pessimistic outlook for the share price and a discouraging interest in betting against Viatris.
Find out more about how you can short Viatris stock.
Environmental, social and governance (known as ESG) criteria are a set of three factors used to measure the sustainability and social impact of companies like Viatris.
When it comes to ESG scores, lower is better, and lower scores are generally associated with lower risk for would-be investors.
Total ESG risk: 37.23
Socially conscious investors use ESG scores to screen how an investment aligns with their worldview, and Viatris's overall score of 37.23 (as at 01/01/2019) is pretty weak – landing it in it in the 78th percentile of companies rated in the same sector.
ESG scores are increasingly used to estimate the level of risk a company like Viatris is exposed to within the areas of "environmental" (carbon footprint, resource use etc.), "social" (health and safety, human rights etc.), and "governance" (anti-corruption, tax transparency etc.).
Environmental score: 1.95/100
Viatris's environmental score of 1.95 puts it squarely in the 2nd percentile of companies rated in the same sector. This could suggest that Viatris is a leader in its sector terms of its environmental impact, and exposed to a lower level of risk.
Social score: 20.21/100
Viatris's social score of 20.21 puts it squarely in the 2nd percentile of companies rated in the same sector. This could suggest that Viatris is a leader in its sector when it comes to taking good care of its workforce and the communities it impacts.
Governance score: 14.07/100
Viatris's governance score puts it squarely in the 2nd percentile of companies rated in the same sector. That could suggest that Viatris is a leader in its sector when it comes to responsible management and strategy, and exposed to a lower level of risk.
Controversy score: 4/5
ESG scores also evaluate any incidences of controversy that a company has been involved in. Viatris scored a 4 out of 5 for controversy – the second-lowest score possible, reflecting that Viatris has a damaged public profile.
|Total ESG score||37.23|
|Total ESG percentile||77.8|
|Environmental score percentile||2|
|Social score percentile||2|
|Governance score percentile||2|
|Level of controversy||4|
We're not expecting Viatris to pay a dividend over the next 12 months. However, you can browse other dividend-paying shares in our guide.
Viatris's shares were split on a 3:2 basis on 9 October 2003. So if you had owned 2 shares the day before before the split, the next day you'd have owned 3 shares. This wouldn't directly have changed the overall worth of your Viatris shares – just the quantity. However, indirectly, the new 33.3% lower share price could have impacted the market appetite for Viatris shares which in turn could have impacted Viatris's share price.
Over the last 12 months, Viatris's shares have ranged in value from as little as $0.077 up to $23.11. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Viatris's is 1.4656. This would suggest that Viatris's shares are more volatile than the average for this exchange and represent, relatively-speaking, a higher risk (but potentially also market-beating returns).
Mylan N.V., together with its subsidiaries, develops, licenses, manufactures, markets, and distributes generic, branded-generic, brand-name, and over-the-counter (OTC) pharmaceutical products in North America, Europe, and internationally. It offers active pharmaceutical ingredients and finished dosage forms; and antiretroviral medicines to treat HIV/AIDS. The company also provides prescription products, such as EpiPen Auto-Injector; Perforomist Inhalation Solution; Dymista; Creon; and Influvac, as well as YUPELRI, an inhalation solution for the maintenance treatment of patients with chronic obstructive pulmonary diseases. In addition, it markets OTC products, including Cold-EEZE, MidNite, Vivarin, Brufen, CB12, and EndWarts. The company offers its products to therapeutic areas, such as cardiovascular, CNS and anesthesia, dermatology, diabetes and metabolism, gastroenterology, immunology, infectious disease, oncology, respiratory and allergy, and women's health. Its customers include retail pharmacies, wholesalers and distributors, payers, and insurers and governments, as well as institutions, such as hospitals. Mylan N.V. has collaboration and license agreements with Pfizer Inc.; Momenta Pharmaceuticals, Inc.; Theravance Biopharma, Inc.; Biocon Ltd.; Fujifilm Kyowa Kirin Biologics Co. Ltd; and Revance Therapeutics, Inc. The company was founded in 1961 and is based in Hatfield, the United Kingdom.
Steps to owning and managing MAX, with 24-hour and historical pricing before you buy.
Steps to owning and managing ICAGY, with 24-hour and historical pricing before you buy.
Steps to owning and managing MAR, with 24-hour and historical pricing before you buy.
Steps to owning and managing HRB, with 24-hour and historical pricing before you buy.
Steps to owning and managing XPEV, with 24-hour and historical pricing before you buy.
Steps to owning and managing LESL, with 24-hour and historical pricing before you buy.
Steps to owning and managing AAL, with 24-hour and historical pricing before you buy.
Steps to owning and managing KMI, with 24-hour and historical pricing before you buy.
Steps to owning and managing CTRC, with 24-hour and historical pricing before you buy.
Steps to owning and managing GEN, with 24-hour and historical pricing before you buy.
finder.com is an independent comparison platform and information service that aims to provide you with the tools you need to make better decisions. While we are independent, the offers that appear on this site are from companies from which finder.com receives compensation. We may receive compensation from our partners for placement of their products or services. We may also receive compensation if you click on certain links posted on our site. While compensation arrangements may affect the order, position or placement of product information, it doesn't influence our assessment of those products. Please don't interpret the order in which products appear on our Site as any endorsement or recommendation from us. finder.com compares a wide range of products, providers and services but we don't provide information on all available products, providers or services. Please appreciate that there may be other options available to you than the products, providers or services covered by our service.